Zobrazeno 1 - 10
of 25
pro vyhledávání: '"556"'
Autor:
Kentaro Kishi, Yasuo Urata, Masaki Mori, Kenta Furukawa, Toshimitsu Irei, Masaki Wakasugi, Masashi Inoue, Shinya Yamashita, Yuichiro Doki, Masahiro Tanemura, Hiroaki Nagano, Nobuyoshi Hatanaka, Hiroki Akamatsu
Publikováno v:
Cancer Research. 75:556-556
Circulating tumor cells (CTCs) are thought to be “metastatic intermediates”. Recently, we reported encouraging survival rates following neoadjuvant therapy using gemcitabine (Gem) and S-1 concurrently with radiotherapy (NACRT) in patients (pts) w
Publikováno v:
Cancer Research. 74:556-556
Background: The pro-inflammatory cytokine, interleukin 32 (IL-32), is a novel tumor marker highly expressed in various human carcinomas including gastric cancer (GC). Materials and Methods: A total of 120 patients with gastric cancer undergoing gastr
Autor:
Hong Seok Choi, Karam Kim
Publikováno v:
Cancer Research. 73:556-556
Interleukin 22 (IL-22), a member of the IL-10 family of cytokines, is secreted T helper 17 (Th17) cells. Although IL-22 was recently reported to be a novel inflammation mediator through STAT3 signaling activation, the precise mechanisms of IL-22 in n
Publikováno v:
Cancer Research. 70:P2-06
Purpose: A strong prognostic impact of urokinase type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor type 1 (PAI-1) as individual factors is well established, with a level of evidence I according to the ASCO recommendat
Autor:
Chelsea Jin, Maher Albitar, Vladislav Chizhevsky, Virginia Burns, Sucha Sudarsanam, Cory Batenchuk
Publikováno v:
Cancer Research. 77:4015-4015
Background: Higher levels of PD-L1 expression at the surface of tumor cells have been associated with increased response to anti-PD-1 therapies (Santabarbara G et al. Ann Transl Med. 2016;4:215; Borghaei H et al. N Engl J Med. 2015;373:1627-1639; Bra
Publikováno v:
Cancer Research. 81:PO-051
Tumor Treating Fields (TTFields) are a non-invasive, loco-regional antimitotic treatment modality, approved for the treatment of glioblastoma and malignant pleural mesothelioma. TTFields at a specific frequency (150-200 kHz) are delivered via arrays
Publikováno v:
Cancer Research. 81:PS14-10
Background: Male breast cancer has been less well studied due to the rarity of this condition compared with female breast cancer. Men have traditionally presented at later stages than women, leading to disparities in outcomes. Our aim was to identify
Autor:
Niall Lennon, Elana Anastasio, Todd R. Golub, K Larken, Dewey Kim, EP Winer, Elizabeth S. Frank, M Krevalin, Eric S. Lander, Corrie A. Painter
Publikováno v:
Cancer Research. 77:P1-05
Background: The Metastatic Breast Cancer Project is a nationwide research initiative that directly engages patients through social media and advocacy groups and seeks to empower them to share their samples and clinical information to accelerate resea
Autor:
Ryan J. Hartmaier, Martin Johnson, Helen Tomkinson, Ganesh Mugundu, James Dunyak, Aleksandra Markovets, Juliann Chmielecki, Karthick Vishwanathan, Carl Barrett, Philip Overend
Publikováno v:
Cancer Research. 80:CT024-CT024
Circulating tumor DNA is released into the bloodstream from tumors and can reflect both intra-tumor heterogeneity and clonal evolution.1 As ctDNA levels are thought to reflect tumor burden, a decrease in ctDNA while on therapy may suggest treatment e
Autor:
Xiaojia Wang, Zefei Jiang, Guyin Lou, Biyun Wang, Zhongsheng Tong, Binghe Xu, Jianfeng Luo, Y. Pan, Zhimin Shao, Yongmei Yin, Li Cai, Changping Wu, Donggeng Liu, Jifeng Feng, Y. Teng, Zhonghua Wang, Joseph Ragaz, Jian Zhang, Xichun Hu, Jiong Wu
Publikováno v:
Cancer Research. 75:P3-10
Background: There is still no standard chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Our previous phase II pilot trial with first-line gemcitabine and cisplatin combination (GP) in patients with mTNBC (clinicaltrial